No Data
2024 Annual Results Forecast
Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Overseas revenue plummets, dragging down performance; the fundraising projects of Ota Biotechnology are delayed.
① Due to the impact of international situations, economic policies, and fluctuations in the overall market, the fundraising projects of Aotai Biological aimed at expanding overseas markets will be delayed. ② Overseas revenue has always been the most core source of income for Aotai Biological, with the overall income proportion once reaching 99.83%, and the sharp decline in overseas revenue has also led to a significant drop in Aotai Biological's overall income.
Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606) CEO Fei Gao, the Company's Largest Shareholder Sees 7.7% Reduction in Holdings Value
Aotai Biotech: Third quarter report 2024
Third Quarter Report 2024
Is Hangzhou Alltest Biotech Co., Ltd.'s (SHSE:688606) Stock Price Struggling As A Result Of Its Mixed Financials?
